1. Home
  2. PIII
  3. Earnings

AI Earnings Predictions for P3 Health Partners Inc. (PIII)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-7.51%

$3.98

0% positive prob.

5-Day Prediction

-18.85%

$3.49

0% positive prob.

20-Day Prediction

-21.63%

$3.37

0% positive prob.

Price at prediction: $4.30 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -7.51% -18.85% -21.63% 100.0% Pending
Q2 2026 SELL -7.12% -12.41% +331.81% 100.0% Pending

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-7.51%

$3.98

Act: -21.18%

5D

-18.85%

$3.49

20D

-21.63%

$3.37

Price: $4.30 Prob +5D: 0% AUC: 1.000
0001832511-26-000045

EX-99.1

2 piii-20261109xexx991.htm

EX-99.1

Document

Exhibit 99.1

P3 Health Partners Announces Third Quarter 2026 Results

Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date

Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint

Management to Host Conference Call and Webcast November 9, 2026 at 4:30 PM ET

HENDERSON, NV—November 9, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2026.

“This was another strong quarter for P3. The foundation we have built over the past two years is showing up both in the care our patients receive and in the consistency of our results. We carry real momentum into 2027, as evidenced by our medical cost trend, and I am excited about what lies ahead for our patients, our providers, and our partners,” said Dr. Aric Coffman, CEO of P3.

Third Quarter 2026 Financial Results

•At-risk membership was approximately 105,000 members for the third quarter, a decrease of 9% compared to prior year, reflecting previously disclosed intentional network and payer rationalization. Total lives under management were approximately 133,500 for the quarter, including the approximately 28,000 lives under management service arrangements.

•Total revenue was $396 million, an increase of 15% compared with the prior year quarter. Total per-member capitated revenue increased 18% from the same period in the prior year driven by improved network economics, rate progression, and burden of illness performance.

•Medical margin(1) for the quarter was $43.9 million, or $140 on a per-member-per-month basis. The results include the favorable impact of payer settlements and prior year development recognized in the quarter. Excluding these items, medical margin for the quarter was $35.0 million, or $111 on a per-member-per-month basis.

•Net income was $30.8 million compared to net loss of $69.5 million in the prior year quarter.

•Adjusted EBITDA(1) for the quarter was $20.9 million, or $66 PMPM, compared to a loss of $45.9 million, or negative $132 per-member-per-month in the prior year quarter.

Revised Fiscal 2026 Guidance

•Full-year revised guidance reflects the increase to the low end of the Adjusted EBITDA range to $90 million, raising the midpoint to $100 million, based on underlying year-to-date performance, as well as the prior-year development and payer settlements recognized in the quarter.

Year Ending December 31, 2026

LowHigh

At-risk Members(2)

102,000106,000

Total Revenues (in millions)$1,525$1,600

Medical Margin(1)(3) (in millions) $260$300

Medical Margin(1)(3) PMPM $210$240

Adjusted EBITDA(1)(3) (in millions) $90$110

(1)Adjusted EBITDA, Adjusted EBITDA per member, per month (“PMPM”), medical margin, and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures, if applicable, and more information regarding the Company’s use of non-GAAP financial measures, please see the section titled “Non-GAAP Financial Measures.”

(2)See “Key Performance Metrics” for additional information on how the Company defines “at-risk members.”

(3)     The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see “Non-GAAP Financial Measures” below.

The foregoing 2026 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the “Cautionary Note Regarding Forward-Looking Statements” included in this release. Management does not assume any obligation to update these estimates.

Management to Host Conference Call and Webcast on November 9, 2026 at 4:30 PM ET

Title & Webcast P3 Health Third Quarter 2026 Earnings Conference Call

Date & Time November 9, 2026, 4:30 PM Eastern Time

Conference Call DetailsToll-Free 1-833-316-0546 (US)

International 1-412-317-0692 Ask to be joined into the P3 Health Partners call

The conference call will also be webcast live in the “Events & Presentations” section of the Investor page of the P3 website (ir.p3hp.org). The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call. An archived recording of the webcast will be available

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 10, 2026 · 100% conf.

AI Prediction SELL

1D

-7.12%

$11.60

Act: -0.96%

5D

-12.41%

$10.94

20D

+331.81%

$53.93

Price: $12.49 Prob +5D: 0% AUC: 1.000
0001832511-26-000032

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K

May 14, 2026

0001832511-26-000021

Transcript text not available. View on SEC.gov →

2025
Q4

Q4 2025 Earnings

8-K

Mar 26, 2026

0001832511-26-000010

Transcript text not available. View on SEC.gov →

2025
Q3

Q3 2025 Earnings

8-K

Nov 14, 2025

0001832511-25-000024

Transcript text not available. View on SEC.gov →

2025
Q2

Q2 2025 Earnings

8-K

Aug 14, 2025

0001832511-25-000010

Transcript text not available. View on SEC.gov →

2025
Q1

Q1 2025 Earnings

8-K

May 15, 2025

0001628280-25-025928

Transcript text not available. View on SEC.gov →

2024
Q4

Q4 2024 Earnings

8-K

Mar 27, 2025

0001628280-25-015165

Transcript text not available. View on SEC.gov →

2024
Q3

Q3 2024 Earnings

8-K

Nov 12, 2024

0001628280-24-047123

Transcript text not available. View on SEC.gov →

2024
Q2

Q2 2024 Earnings

8-K

Aug 7, 2024

0001628280-24-035600

Transcript text not available. View on SEC.gov →

2024
Q1

Q1 2024 Earnings

8-K

May 8, 2024

0001628280-24-021663

Transcript text not available. View on SEC.gov →

2023
Q4

Q4 2023 Earnings

8-K

Mar 28, 2024

0001628280-24-013613

Transcript text not available. View on SEC.gov →

2023
Q4

Q4 2023 Earnings

8-K

Jan 10, 2024

0001628280-24-000993

Transcript text not available. View on SEC.gov →

2023
Q3

Q3 2023 Earnings

8-K

Nov 8, 2023

0001628280-23-037818

Transcript text not available. View on SEC.gov →

2023
Q2

Q2 2023 Earnings

8-K

Aug 7, 2023

0001628280-23-027768

Transcript text not available. View on SEC.gov →

2023
Q1

Q1 2023 Earnings

8-K

May 10, 2023

0001628280-23-017225

Transcript text not available. View on SEC.gov →

2022
Q4

Q4 2022 Earnings

8-K

Mar 31, 2023

0001104659-23-039608

Transcript text not available. View on SEC.gov →

2022
Q4

Q4 2022 Earnings

8-K

Mar 15, 2023

0001104659-23-032430

Transcript text not available. View on SEC.gov →

2022
Q4

Q4 2022 Earnings

8-K

Jan 11, 2023

0001104659-23-003071

Transcript text not available. View on SEC.gov →

2022
Q3

Q3 2022 Earnings

8-K

Nov 14, 2022

0001104659-22-118322

Transcript text not available. View on SEC.gov →

About P3 Health Partners Inc. (PIII) Earnings

This page provides P3 Health Partners Inc. (PIII) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on PIII's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: